Baricitinib (LY3009104): Mechanism of Action

Baricitinib (LY3009104) MOA:Targeting JAK1/JAK-STAT Signaling Pathway for Coronavirus Disease 2019

🎯 check Baricitinib (LY3009104) product page

Baricitinib (LY3009104) is a potent, selective, and reversible JAK1/2 inhibitor. It affects the JAK/STAT signaling pathway by inhibiting JAK kinase activity and preventing STAT phosphorylation, effectively suppressing inflammation, immune cell activation, fibrosis, and viral infectivity.

Primary Applications and Mechanism of Action